Anti-Canakinumab Antibodies
-
Bioanalytical Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
-
Our Anti-Biotherapeutic Antibodies
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Aflibercept Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Atezolizumab Antibodies
- Anti-Avelumab Antibodies
- Anti-Belatacept Antibodies
- Anti-Belimumab Antibodies
- Anti-Benralizumab Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Burosumab Antibodies
- Anti-Canakinumab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dulaglutide Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Elotuzumab Antibodies
- Anti-Emicizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Guselkumab Antibodies
- Anti-Ixekizumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Nirsevimab Antibodies
- Anti-Obinutuzumab Antibodies
- Anti-Ocrelizumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ramucirumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Risankizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Romosozumab Antibodies
- Anti-Sarilumab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Tremelimumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
- Anti-Isatuximab Antibodies
-
Our Anti-Biotherapeutic Antibodies
-
Antibodies for Bioanalysis and Drug Monitoring
s
s
s
Antibodies for bioanalysis and drug monitoring of canakinumab
Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug canakinumab (Ilaris) using our range of ready-made anti-idiotypic antibodies.
- Inhibitory antibodies specific to canakinumab and the canakinumab-IL-1β complex
- Fully human surrogate positive control or calibrator
- Sequence defined, well characterized reagents with secure supply
- Recombinant production, stringent quality control for batch-to-batch consistency
- Non-animal-derived antibodies, reducing the use of animals in science
Table 1. Antibodies Specific to Canakinumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Canakinumab |
HCA417 |
AbD54331ia |
hIgG1 |
1.5 |
ADA assay |
|
|
HCA418 |
AbD54111ia |
hIgG1 |
7.7 |
ADA assay |
||
|
HCA419 |
AbD54116ia |
hIgG1 |
9.6 |
ADA assay |
||
|
TZA063 |
AbD54116ad |
Fab-F-Spy2-H1 |
9.6 |
PK bridging ELISA (capture) |
||
|
TZA064 |
AbD54331ad |
Fab-F-Spy2-H1 |
1.5 |
PK bridging ELISA (detection) |
||
|
TZA064P |
AbD54331pap |
Fab2-FH-X22-HRP2 |
1.5 |
PK bridging ELISA (detection) |
||
|
Canakinumab-IL-1β Complex Specific |
TZA0112 |
AbD54142ad |
Fab-F-Spy2-H1 |
3.3 |
PK antigen capture (detection) |
|
|
TZA0112P |
AbD54142pap |
Fab2-FH-X22-HRP2 |
3.3 |
PK antigen capture (detection) |
* Affinity measured in the monovalent Fab format.
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher.
Anti-Canakinumab Inhibitory Antibodies (Type 1)
Type 1 anti-canakinumab antibodies inhibit the binding of the drug canakinumab to its target, the human interleukin-1β (IL-1β). They are ideal for the development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibodies in fully human IgG1 format are suitable as surrogate positive controls or calibrators for an anti-drug antibody (ADA) assay.
Anti-Canakinumab-IL-1β Complex-Specific Antibody (Type 3)
The Type 3 antibody specifically recognizes the drug-target complex, detecting canakinumab only when it is bound to IL-1β. It is suitable as a detection antibody in a PK antigen capture assay.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Canakinumab PK bridging ELISA using antibodies TZA063 and TZA064P.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.
PK Antigen Capture ELISA
Fig. 2. Canakinumab PK antigen capture ELISA using TZA0112P
Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), labeled with HRP.
ADA Bridging ELISA
Fig. 3. Canakinumab ADA bridging ELISA using antibodies HCA417, HCA418, and HCA419.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.